Literature DB >> 25811445

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Woocheol Kwon1, Brandon A Howard, James E Herndon, Edward F Patz.   

Abstract

INTRODUCTION: Patients with stage I non-small-cell lung cancer (NSCLC) have a wide variation in outcomes, most likely because there are undetected metastases at presentation. We retrospectively reviewed patients with early stage lung cancer to determine if FDG uptake of the primary tumor as measured on positron emission tomography (PET) at the time of diagnosis was associated with overall survival (OS) or time to recurrence (TTR).
METHODS: We reviewed the Tumor Registry at our institution and identified 336 consecutive patients diagnosed with stage I NSCLC over a 5-year period who underwent an FDG-PET/computed tomography within 90 days before surgery. Kaplan-Meier curves were used to describe the survival and TTR experience within subgroups defined by PET maximum standardized uptake value (SUVmax). Cox proportional hazards model was used to assess the impact of PET SUVmax as a continuous variable on OS and TTR. Logistic regression was used to analyze the effect of SUVmax on dichotomized outcomes.
RESULTS: Three hundred thirty-six consecutive patients (176 women and 160 men) with stage I NSCLC were retrospectively reviewed. Mean SUVmax was 9.2 ± 6.9 (range 0.6-30.3). The hazard or risk of dying and recurrence increased significantly as SUVmax increased (p = 0.0008 and 0.024, respectively).
CONCLUSIONS: Preoperative FDG uptake in the primary tumor in patients with stage I disease is associated with OS and TTR. This may be useful in identifying early stage patients who may benefit from more aggressive therapy after surgical resection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25811445     DOI: 10.1097/JTO.0000000000000534

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

1.  Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy.

Authors:  Madison R Kocher; Anand Sharma; Elizabeth Garrett-Mayer; James G Ravenel
Journal:  J Comput Assist Tomogr       Date:  2018 Jan/Feb       Impact factor: 1.826

Review 2.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

3.  Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy.

Authors:  Anastasia Oikonomou; Farzad Khalvati; Pascal N Tyrrell; Masoom A Haider; Usman Tarique; Laura Jimenez-Juan; Michael C Tjong; Ian Poon; Armin Eilaghi; Lisa Ehrlich; Patrick Cheung
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

4.  [Formula: see text]: deep learning-based radiomics for the time-to-event outcome prediction in lung cancer.

Authors:  Parnian Afshar; Arash Mohammadi; Pascal N Tyrrell; Patrick Cheung; Ahmed Sigiuk; Konstantinos N Plataniotis; Elsie T Nguyen; Anastasia Oikonomou
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

5.  Enhanced glucose metabolism mediated by CD147 is associated with 18 F-FDG PET/CT imaging in lung adenocarcinoma.

Authors:  Yufan Zhang; Jianjing Liu; Yunchuan Sun; Xiaozhou Yu; Jian Wang; Dong Dai; Yanjia Zhu; Xiuyu Song; Lei Zhu; Xiaofeng Li; Wengui Xu
Journal:  Thorac Cancer       Date:  2020-03-11       Impact factor: 3.500

6.  Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.

Authors:  Ran Zhang; Changbin Wang; Kai Cui; Yicong Chen; Fenghao Sun; Xiaorong Sun; Ligang Xing
Journal:  Cancer Manag Res       Date:  2019-11-25       Impact factor: 3.989

7.  Clinical significance of PET/CT uptake for peripheral clinical N0 non-small cell lung cancer.

Authors:  Shuai Wang; Dong Lin; Xiaodong Yang; Cheng Zhan; Shihai Zhao; Rongkui Luo; Qun Wang; Lijie Tan
Journal:  Cancer Med       Date:  2020-02-13       Impact factor: 4.452

8.  Prognostication Based on Texture Analysis of Baseline 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Nonsmall-Cell Lung Carcinoma Patients Who Underwent Platinum-Based Chemotherapy as First-Line Treatment.

Authors:  Akshima Sharma; Anil Kumar Pandey; Anshul Sharma; Geetanjali Arora; Anant Mohan; Ashu Seith Bhalla; Lalit Gupta; Shiba Kalyan Biswal; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2021-09-23

Review 9.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

10.  Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma.

Authors:  Guotao Yin; Ziyang Wang; Yingchao Song; Xiaofeng Li; Yiwen Chen; Lei Zhu; Qian Su; Dong Dai; Wengui Xu
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.